To The Editor: Dr Mukherjee and colleagues1 present the CV event data from CLASS study (Figure
2) in an inconsistent fashion. Summary data from the US Food and Drug Administration
hearings on the safety of celecoxib during the CLASS trial2
are the primary source for this figure. Review of these data reveals that
MI and stroke rates are presented as crude event rates while deaths are displayed
as annualized incidence rates. Moreover, deaths include all cause deaths,
rather than CV deaths. The correct crude event rates for CV deaths in CLASS
are 0.57% (aspirin users) and 0.16% (non-aspirin users).2
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 3
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.